Literature DB >> 16044425

Malignant transformation of high-grade anal intraepithelial neoplasia.

J H Scholefield1, M T Castle, N F S Watson.   

Abstract

BACKGROUND: The natural history of anal intraepithelial neoplasia (AIN) is uncertain. This makes management problematic as treatment options to eradicate the condition carry morbidity. The authors report their 10-year experience with conservative management of this condition, highlighting the lessons learnt.
METHODS: All patients were diagnosed with high-grade AIN (AIN III) between 1994 and 2003. Diagnosis was by full-thickness biopsy and histopathological examination. Excision of localized lesions was undertaken, and all patients underwent follow-up every 6 months. Prospective data were collected regarding recurrence, postoperative complications and progression to invasive carcinoma.
RESULTS: Thirty-five patients were followed for a median of 63 (range 14-120) months. Excision of localized high-grade AIN was carried out in 28 patients with minimal morbidity. Six patients were systemically immunosuppressed at diagnosis, all of whom had multifocal perianal lesions. Three immunosuppressed patients developed invasive anal squamous carcinoma during follow-up. By contrast, no invasive carcinomas were identified among immunocompetent patients with either localized or multifocal perianal disease.
CONCLUSION: AIN III appears to have a relatively low potential for malignant transformation in the immunocompetent patient. However, immunosuppressed patients are more likely to have extensive AIN III and a greater risk of malignant change. Copyright 2005 British Journal of Surgery Society Ltd.

Entities:  

Mesh:

Year:  2005        PMID: 16044425     DOI: 10.1002/bjs.4994

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  45 in total

Review 1.  Vaccinations for Anal Squamous Cancer: Current and Emerging Therapies.

Authors:  John Berry; Sean C Glasgow
Journal:  Clin Colon Rectal Surg       Date:  2018-11-02

Review 2.  Anal Intraepithelial Neoplasia and Squamous Cell Cancer of the Anus.

Authors:  Rebecca E Hoedema
Journal:  Clin Colon Rectal Surg       Date:  2018-11-02

Review 3.  Multidisciplinary Approach to the Management and Treatment of Anal Dysplasia.

Authors:  Jeffrey Douaiher; Sean J Langenfeld
Journal:  Clin Colon Rectal Surg       Date:  2018-11-02

Review 4.  Advances in the Management of Anal Cancer.

Authors:  Diana R Julie; Karyn A Goodman
Journal:  Curr Oncol Rep       Date:  2016-03       Impact factor: 5.075

Review 5.  Anal cancer and intraepithelial neoplasia: epidemiology, screening and prevention of a sexually transmitted disease.

Authors:  Richard J Medford; Irving E Salit
Journal:  CMAJ       Date:  2014-12-15       Impact factor: 8.262

6.  Risk of Invasive Anal Cancer in HIV-Infected Patients With High-Grade Anal Dysplasia: A Population-Based Cohort Study.

Authors:  Yotam Arens; Michael Gaisa; Stephen E Goldstone; Yuxin Liu; Juan Wisnivesky; Carlie S Sigel; Talia H Swartz; Keith Sigel
Journal:  Dis Colon Rectum       Date:  2019-08       Impact factor: 4.585

7.  High resolution anoscopy in the planned staged treatment of anal squamous intraepithelial lesions in HIV-negative patients.

Authors:  Carlos E Pineda; J Michael Berry; Naomi Jay; Joel M Palefsky; Mark L Welton
Journal:  J Gastrointest Surg       Date:  2007-08-21       Impact factor: 3.452

8.  Evaluation and Management of Anal Intraepithelial Neoplasia in HIV-Negative and HIV-Positive Men Who Have Sex with Men.

Authors:  Ina U Park; Joel M Palefsky
Journal:  Curr Infect Dis Rep       Date:  2010-02-24       Impact factor: 3.725

9.  Anal dysplasia screening: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2007-06-01

Review 10.  HPV and anal cancer in HIV-infected individuals: a review.

Authors:  Maarten F Schim van der Loeff; Sofie H Mooij; Oliver Richel; Henry J C de Vries; Jan M Prins
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.